Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease
Authors:
- Jacqueline PearsonJPJacqueline Pearson
- Daniel A. RogersDRDaniel A. Rogers
- Ge LuGLGe Lu
- Vilte E. BarakauskasVBVilte E. Barakauskas
- Alasdair M. BarrABAlasdair M. Barr
- William G. HonerWHWilliam G. Honer
- Michael R. HaydenMHMichael R. Hayden
- Blair R. LeavittBLBlair R. Leavitt
- 1 December 2005
- journal article
- research article
- Published by Elsevier in Experimental Neurology
- Vol. 196 (2) , 266-272
Abstract
No abstract availableKeywords
Funding Information
- Huntington Society of Canada
- Canadian Institutes of Health Research
- Huntington's Disease Foundation
- Herb Society of America
- Michael Smith Health Research BC
This publication has 26 references indexed in Scilit:
- Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington diseaseJournal of Neurochemistry, 2005
- Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's DiseaseJournal of Neuroscience, 2005
- Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington diseaseHuman Molecular Genetics, 2005
- Neuroprotective actions of eicosapentaenoic acid on lipopolysaccharide‐induced dysfunction in rat hippocampusJournal of Neurochemistry, 2004
- A review of the treatment options for Huntington’s diseaseExpert Opinion on Pharmacotherapy, 2004
- Eicosapentaenoic Acid Protects Endothelial Cells Against Anoikis Through Restoration of cFLIPHypertension, 2003
- Apoptotic Changes in the Aged Brain Are Triggered by Interleukin-1β-induced Activation of p38 and Reversed by Treatment with Eicosapentaenoic AcidJournal of Biological Chemistry, 2002
- Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutaminesNature Neuroscience, 2002
- Neuroprotective Effect of Eicosapentaenoic Acid in Hippocampus of Rats Exposed to γ-IrradiationJournal of Biological Chemistry, 2002
- N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntingtonʼs disease miceNeuroReport, 2000